Cytotoxic chemotherapeutic agents under development with a possible future role in prostate cancer.

New cytotoxic chemotherapeutic compounds under development or in early clinical trial which might be considered for clinical evaluation in prostatic carcinoma are discussed. The following classes of agents are considered: lipid-soluble antifolates, anthracyclines, nitrosoureas, and platinum analogues. A group of miscellaneous compounds is also discussed.